IDEXX Raises 2026 EPS Guidance to $14.69-$14.94 on Strong Q2
IDXX is trading near its 52-week low of $518.55 (14% above the low) on elevated volume (1.8× avg).
Summary
IDEXX raised its full-year 2026 EPS guidance to $14.69-$14.94, up from prior expectations, following strong Q2 results with double-digit revenue and EPS growth. The new range implies a material step-up in profitability, reflecting sustained demand in the companion animal diagnostics market. This follows the 8-K filed earlier today confirming the Q2 beat and the raised outlook. The guidance raise signals management confidence in the back half of the year, with the stock likely to react positively as analysts revise estimates upward. IDEXX Labs reported higher Q2 profit on strong revenue growth and lifted its full-year earnings outlook, with the stock trading up.
At the time of this announcement, IDXX was trading at $588.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.8B. The 52-week trading range was $518.55 to $769.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.